Sartorius Stedim Biotech SA / Key word (s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST ...

Sales revenue at 745 million euros, up 10.4 percent in constant currencies 1 (reported: 11.7 percent) Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, started the fiscal ...

Sartorius Stedim Biotech reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales and adjusted EBITDA increased in constant currency by 10.4% and 19.9% ...

Sartorius Stedim Biotech SA (SDMHF) reports robust Q1 2025 results with significant growth in Bioprocess Solutions and improved financial metrics. Sartorius Stedim Biotech SA (SDMHF) reports steady ...

Guidance for 2025 EBITDA Margin: Expected between 29% to 30%. Sartorius Stedim Biotech SA (SDMHF) reported a strong start to 2025 with a 10% increase in sales revenue for Bioprocess Solutions ...

Sartorius Stedim Biotech SA (DIM), with a market capitalization of $135.93 million, reported robust earnings for the first quarter of 2025, exceeding analyst expectations with an earnings per ...

The chart above depicts the trend in analyst earnings per share (EPS) forecasts for Sartorius Stedim Biotech for the upcoming quarter. Analysts have not changed this quarter's expectations for EPS ...

Guidance for 2025 EBITDA Margin: Expected between 29% to 30%. Sartorius Stedim Biotech SA (SDMHF) reported a strong start to 2025 with a 10% increase in sales revenue for Bioprocess Solutions, driven ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell ...